Daily dose of alfacalcidol at conversion from intravenous maxacalcitol in secondary hyperparathyroidism management

Ther Apher Dial. 2022 Apr;26(2):471-472. doi: 10.1111/1744-9987.13751. Epub 2021 Nov 11.

Authors

Masayuki Tanemoto^{1

2}, Takahide Kimura¹, Seiki Yamada¹

Affiliations

¹ Division of Nephrology, Department of Internal Medicine, International University of Health and Welfare School of Medicine, Atami, Shizuoka, Japan.
² Dialysis Unit, Shin-Kuki General Hospital, Saitama, Japan.

PMID: 34738309
DOI: 10.1111/1744-9987.13751

No abstract available

Publication types

Letter

MeSH terms

Calcitriol / analogs & derivatives
Calcium
Humans
Hydroxycholecalciferols / therapeutic use
Hyperparathyroidism, Secondary* / drug therapy
Hyperparathyroidism, Secondary* / etiology
Parathyroid Hormone
Renal Dialysis

Substances

Hydroxycholecalciferols
Parathyroid Hormone
Calcitriol
maxacalcitol
Calcium
alfacalcidol